

METHODS

Mice, cells and reagents. *Trib1*^{-/-} mice were generated as described previously¹¹. Antibodies for flow cytometry were purchased from commercial sources as follows: anti-F4/80-FITC (BM8; BioLegend); anti-Mac1-PerCP Cy5.5 (M1/70; BD Biosciences); anti-Ly6C-FITC (AL-21; BD Biosciences); anti-Siglec-F-PE (E50-2446; BD Biosciences); anti-CCR3-APC (83103; BD Biosciences); anti-MR-Alexa 488 (MR5D3; BioLegend); and anti-CD11c-Brilliant bright (N418; BioLegend). Antibodies and reagents for histochemical analysis were purchased from commercial sources as follows: biotinylated anti-F4/80 (eBioscience), anti-MOMA-1 (Abcam), Alexa 488-conjugated anti-B220 (BD Pharmingen) and streptavidin-Alexa594 (Invitrogen). Antibodies for western blotting were purchased as follows: anti-C/EBP α (no. 2295; Cell Signaling Technology); anti-C/EBP β (no. E298; Millipore); anti-C/EBP δ (no. 2318; CST); anti-C/EBP ϵ (no. sc-158; Santa Cruz Biotechnology); and anti-actin (no. sc-1615; Santa Cruz Biotechnology). The probes for quantitative PCR were purchased from Lifescience Japan.

Generation of *Trib2*^{-/-} and *Trib3*^{-/-} mice. The *Trib2* and *Trib3* genes were isolated from genomic DNA extracted from embryonic stem (ES) cells (GSF-1) by PCR. The targeting vectors were constructed by replacing a 2-kilobase (kb) fragment encoding the *Trib2* open reading frame (exon 2) and replacing a 2.5-kb fragment encoding the *Trib3* open reading frame (exons 2–3) with a neomycin-resistance gene cassette (*neo*), and inserting herpes simplex virus thymidine kinase (HSV-TK) driven by the PGK promoter into the genomic fragment for negative selection. After each targeting vector was transfected into ES cells, G418 and ganciclovir double-resistant colonies were selected and screened by PCR, and recombination was further confirmed by Southern blotting. The homologous recombinant clones were individually microinjected into blastocysts derived from C57BL/6 mice and then transferred to pseudopregnant females. Mating of chimaeric male mice with C57BL/6 female mice resulted in the transmission of each mutant allele to the germ line. The resulting *Trib2*^{+/-} and *Trib3*^{+/-} mice were interbred to generate *Trib2*^{-/-} and *Trib3*^{-/-} mice, respectively. All animal experiments were performed with approval from the Animal Research Committee of the Research Institute for Microbial Diseases (Osaka University).

Construction of expression plasmids and shRNA vectors. *Trib1* and *Cebpa* cDNAs were obtained by PCR from a mouse cDNA library. Full-length or mutated *Trib1* cDNAs were cloned into the pLZR-cmv-ires-GFP vector for retrovirus production. For shRNA experiments, the following oligonucleotides were used to target mouse C/EBP α : *cebpa*-8 dn, 5'-gatccGTCGTATGTATTATATCTATA TTCAAGAGATATAGATAAATACATACGACTTTTTTACGCGTg-3' and *cebpa*-8 up, 5'-aattcACGCGTAAAAAGTCTGATGTATTATCTATATCTCTTGAATATAGATAAATACATACGACg-3'; *cebpa*-12 dn, 5'-gatccATCC GATATCAACACTTGTATTTCAGAGAATAACAAGTGTGATATCGGATT TTTTACGCGTg-3' and *cebpa*-12 up, 5'-aattcACGCGTAAAAAATCCGA TATCAACACTTGTATTCTCTTGAATACAAGTGTGATATCGGATg-3'. The oligonucleotides were annealed and ligated with the RNAi-ready pSIREN-RetroQ-zsGreen vector (Takara). Lowercase letters indicate the site of restriction enzyme.

Colony-forming assay. Bone marrow cells (4×10^4) were seeded on 3.5-cm dishes and cultured for 7 days with Methocult (no. 3534; Stem Cell Technologies) containing SCF, IL-6 and IL-3 in the presence of 20 ng ml^{-1} M-CSF. The numbers of GFP-positive cells were counted for colony-forming assays or collected for real-time (q)PCR and western blotting.

Assessment of glucose, insulin and NEFA levels and glucose and insulin sensitivity *in vivo*. Serum insulin levels were determined by ELISA (Morinaga Institute of Biological Science Inc.). Serum glucose, NEFA and cholesterol levels were measured with enzymatic kits (WAKO Chemicals). Intraperitoneal glucose tolerance tests were performed on 16 h fasted mice injected intraperitoneally with D-glucose (1.5 mg g^{-1} body weight). Serum glucose levels were measured immediately before and 30, 60, 90 and 120 min after the D-glucose injection. Intraperitoneal insulin tolerance tests were performed on 4 h fasted mice injected intraperitoneally with insulin (1 mU g^{-1} body weight). Serum glucose levels were measured immediately before and 15, 30, 60 and 90 min after the insulin injection.

Lipolysis assay. *In vivo* lipolysis assays were performed on 4 h fasted mice. Blood was collected from orbital veins, and the serum glycerol and NEFA concentrations were measured.

Quantitative PCR analysis. Total RNA was isolated using Trizol (Invitrogen) and subjected to reverse transcription with ReverTra Ace (Toyobo) according to the manufacturer's instructions. For quantitative PCR, cDNA fragments were amplified using real-time PCR Master Mix (Toyobo). Fluorescence from the TaqMan probe for each cytokine was detected using a 7500 Real-time PCR System (Applied Biosystems). To determine the relative induction of each cytokine mRNA in response to various stimuli, the mRNA expression level of each gene was normalized to the 18S rRNA expression level. The experiments were repeated at least twice.

Assay ID numbers are: *Arg1*, Mm00475988_m1, *Ym1*, Mm00657889_mH, *Fizz1*, Mm00445109_m1, *MR*, Mm00485148_m1; *Trib1*, Mm00454875_m1; *Trib2*, Mm0045 4876_m1; *Trib3*, Mm00454879_m1; *Acaca*, Mm01304277_m1; *Fasn*, Mm00662319_m1; *Acs1*, Mm00484217_m1; *PParg*, Mm01184322_m1; *Cebpa*, Mm00514283_s1; *Cebpb*, Mm00843434_s1; *Cebpd*, Mm00786711_s1; *I110*, Mm00439614_m1; *Tnfrfa*, Mm99999068_m1; *Inos*, Mm00440485_m1.

Immunoblot analysis. Bone marrow cells were collected and red blood cells were lysed using red blood cell lysis buffer (Invitrogen). After two washes with MACS buffer, lineage-negative cells were collected by MACS sorting using anti-CD3, anti-CD19, anti-B220, anti-Ter119, anti-Gr1, anti-DX5, anti-Mac1 and anti-CD11c MACS beads (Miltenyi Biotec). The lineage-negative cells were lysed with lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP40) containing Complete Protease Inhibitor Cocktail (Roche). The cell lysates were separated by standard SDS-PAGE and analysed by immunoblotting. Antibodies against the following proteins were used: C/EBP α , C/EBP β , C/EBP δ , C/EBP ϵ and actin. The Luminata Forte Western HRP Substrate (Millipore) was used for the development of positive signals.

Flow cytometry. Cell suspensions were prepared by sieving and gentle pipetting. After washing with ice-cold FACS buffer (0.5% BSA and 2 mM EDTA in PBS, pH 7.2), the cells were incubated with antibodies for 15 min and washed twice with FACS buffer. Data were acquired using a FACSCalibur flow cytometer (BD), and analysed by FlowJo software (Tree Star).

Retroviral preparation. Retroviruses were produced using PlatE packaging cells or transfected with various plasmids. Bone marrow cells were transduced with the retroviral supernatants (supplemented with polybrene (Millipore)) twice. After the second transduction, the cells were washed twice and re-suspended in RPMI medium.

Magnetic resonance imaging (MRI). An 11.7 T MRI scanner (AVANCE-II 500 WB; Bruker BioSpin) was used to acquire *in vivo* mouse images. Mice were anesthetized with 1.0–1.5% isoflurane during the MRI procedures. We used a T₂-weighted imaging sequence (RARE) with the following parameters: field of view, 2.5×2.5 cm; matrix size, 256×256 ; slice thickness, 0.5 mm; repetition time, 5,000 ms; echo time, 25.2 ms; average, 4; scan time, 5 min.

Histochemical analysis. Frozen 6- μm tissue sections were fixed in 4% paraformaldehyde and blocked with 5% BSA (Invitrogen). For Perl's Prussian blue staining, tissues were fixed with 4% paraformaldehyde in phosphate buffer (pH 7.0), embedded in paraffin and stained with Perl's Prussian blue.

Generation of bone-marrow-transferred chimaeric mice. Bone marrow cells were prepared from wild-type and *Trib1*^{-/-} mice, and intravenously injected into lethally irradiated CD45.1 C57BL/6 mice, wild-type and *Trib1*^{-/-} mice. The chimaeric mice were administered neomycin (Sigma) and polymyxin B (Sigma) in their drinking water for 8 weeks. The mice were analysed for at least 12 weeks after reconstitution. More than 90% of splenocytes from the chimaeric mice were CD45.2⁺.

Mouse SVF and MAF isolation. Epididymal fat pads from male mice fed a normal or HFD were excised and minced in Krebs-Ringer-bicarbonate-HEPES buffer (KRBH: 120 mM NaCl, 4 mM KH₂PO₄, 1 mM MgSO₄, 1 mM CaCl₂, 10 mM NaHCO₃, 30 mM HEPES, 20 μM adenosine (Sigma), 4% BSA). The tissues were then digested with 1 mg ml^{-1} collagenase type II (Sigma) in PBS at 37°C for 30 min with gentle shaking and filtered through a 100- μm filter. In SVF preparations, the digested cells were separated by centrifugation at 700g for 5 min. In MAF preparations, the digested cells were separated by centrifugation at 300g for 5 min. The resulting cells were washed twice with KRBH buffer before use in experiments.

Metabolic measurements. Serum insulin levels were determined by ELISA (Morinaga Institute of Biological Science Inc.). Serum glucose, NEFA and cholesterol levels were measured with enzymatic kits (WAKO Chemicals). Intraperitoneal glucose tolerance tests were performed on 16 h fasted mice injected intraperitoneally with D-glucose (1.5 mg g^{-1} body weight). Serum glucose levels were measured immediately before administration and 30, 60, 90 and 120 min after the D-glucose injection.

Lipolysis assay. *In vivo* lipolysis assays were performed on 4 h fasted mice. Blood was collected from orbital veins, and the serum glycerol and NEFA concentrations were measured. For *ex vivo* assays, adipocytes were isolated from epididymal pads using collagenase, washed twice, re-suspended in Krebs-Ringer buffer at 5×10^5 cells ml⁻¹ and incubated with shaking for the specified times. The glycerol and NEFA concentrations were measured in the supernatants.

Microarray analysis. Total RNA was isolated from wild-type and *Trib1*^{-/-} GMP and MDP using TRIzol RNA isolation kit (Invitrogen) and further purified using an RNeasy kit (Qiagen). Biotinylated cDNA was synthesized from 100 ng total RNA with the Ovation biotin RNA amplification and labelling systems (Nugen) according to the manufacturer's protocol. The product was purified using an DyeEx 2.0 spin kit (QIAGEN), fragmented, and hybridized to Affymetrix mouse

expression array A430 2.0 microarray chips, according to the manufacturer's protocol (Affymetrix). Staining, washing and scanning of Affymetrix mouse Genome 430 2.0 microarray chips was done following the manufacturer's instructions. Robust multichip average (RMA) expression values were calculated using R and the Bioconductor affy package. For each probe the changes in expression between wild-type and *Trib1*^{-/-} samples were defined as the difference between

\log_2 values for wild-type and *Trib1*^{-/-} cells. Genes were assigned the values of their corresponding probe(s). In cases where a gene was associated with multiple probes the average value was taken.

Statistical analysis. The statistical significance of differences between values was calculated using the two-tailed Student's *t*-test. Values of **P* < 0.05, ***P* < 0.01 were considered to indicate statistical significance.

Tumorigenesis and Neoplastic Progression

Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer

Shinji Takeuchi,* Wei Wang,*[†] Qi Li,*[‡]
Tadaaki Yamada,* Kenji Kita,* Ivan S. Donev,*
Takahiro Nakamura,[§] Kunio Matsumoto,[§]
Eiji Shimizu,[¶] Yasuhiko Nishioka,^{||} Saburo Sone,^{||}
Takayuki Nakagawa,*^{***} Toshimitsu Uenaka,^{**} and
Seiji Yano*

From the Divisions of Medical Oncology* and Tumor Dynamics and Regulation,[§] Cancer Research Institute, Kanazawa University, Kanazawa, Japan; the Departments of Radiation Oncology[†] and Gastroenterology,[‡] Nanfang Hospital, Southern Medical University, Guangzhou, China; the Division of Medical Oncology and Molecular Respiratory,[¶] Faculty of Medicine, Tottori University, Yonago, Japan; the Department of Respiratory Medicine and Rheumatology,^{||} University of Tokushima Graduate School, Tokushima, Japan; and the Tsukuba Research Laboratories,^{**} Eisai Co. Ltd., Tsukuba, Japan

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a serious problem in the management of EGFR mutant lung cancer. We recently reported that hepatocyte growth factor (HGF) induces resistance to EGFR-TKIs by activating the Met/PI3K pathway. HGF is also known to induce angiogenesis in cooperation with vascular endothelial growth factor (VEGF), which is an important therapeutic target in lung cancer. Therefore, we hypothesized that dual inhibition of HGF and VEGF may be therapeutically useful for controlling HGF-induced EGFR-TKI-resistant lung cancer. We found that a dual Met/VEGF receptor 2 kinase inhibitor, E7050, circumvented HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer cell lines by inhibiting the Met/Gab1/PI3K/Akt pathway *in vitro*. HGF stimulated VEGF production by activation of the Met/Gab1 signaling pathway in EGFR mutant lung cancer cell lines, and E7050 showed an inhibitory effect. In a xenograft model, tumors produced by HGF-transfected Ma-1 (Ma-1/HGF) cells were more angiogenic than vector control tumors and showed resistance to gefitinib. E7050 alone inhibited angiogenesis and retarded growth of Ma-1/HGF tumors. E7050 combined

with gefitinib induced marked regression of tumor growth. Moreover, dual inhibition of HGF and VEGF by neutralizing antibodies combined with gefitinib also markedly regressed tumor growth. These results indicate the therapeutic rationale of dual targeting of HGF-Met and VEGF-VEGF receptor 2 for overcoming HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. (Am J Pathol 2012, 181:1034–1043; <http://dx.doi.org/10.1016/j.ajpath.2012.05.023>)

Lung cancer is the leading cause of malignancy-related death worldwide. Recently, two types of molecularly targeted therapy, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and the angiogenesis inhibitor bevacizumab, have been successfully introduced in the treatment of lung cancer.¹ The reversible EGFR-TKIs gefitinib and erlotinib show dramatic therapeutic efficacy in patients with EGFR-activating mutations, such as in-frame deletion in exon 19 and L858 point mutation in exon 21.^{2,3} Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody (Ab), enhances the efficacy of cytotoxic chemotherapy and prolongs survival in nonsquamous non-small-cell lung cancer.⁴ However, disease progression due to intrinsic or acquired resistance always occurs even in cases treated with these molecularly targeted drugs. In fact, although reversible EGFR-TKIs show a response rate of

Supported by Grants-in-Aid for Cancer Research (21390256 to S.Y.); Scientific Research on Innovative Areas "Integrative Research on Cancer Microenvironment Network" from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (22112010A01 to S.Y.); and Eisai Co. Ltd. and National Natural Science Foundation of China (81172243 to W.W.).

Accepted for publication May 17, 2012.

S.Y. obtained research grants from Eisai Co. Ltd. and Chugai Pharm and speaker fees from Chugai Pharma and AstraZeneca. T. Nakag. and T.U. are employees of Eisai Co. Ltd.

Supplemental material for this article can be found at <http://ajp.amjpathol.org> or at <http://dx.doi.org/10.1016/j.ajpath.2012.05.023>.

Address reprint requests to Seiji Yano, M.D., Ph.D., Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa 920-0934, Japan. E-mail: syano@staff.kanazawa-u.ac.jp.

70% to 80% and significantly longer progression-free survival compared with standard first-line cytotoxic chemotherapy in *EGFR* mutant lung cancer,^{5,6} patients almost always develop acquired resistance to EGFR-TKIs after varying periods.⁷ In addition, 20% to 30% of patients with *EGFR*-activating mutations exhibit intrinsic resistance to EGFR-TKIs.⁷ Therefore, intrinsic and acquired resistance to EGFR-TKIs is a major problem in the management of *EGFR* mutant lung cancer.

Recent studies documented three clinically relevant mechanisms—*EGFR* T790M secondary mutation (T790M secondary mutation),^{8,9} *Met* gene amplification,¹⁰ and hepatocyte growth factor (HGF) overexpression¹¹—that induce acquired resistance to EGFR-TKIs in *EGFR* mutant lung cancer. Of these mechanisms, HGF overexpression is involved in not only acquired resistance but also intrinsic resistance. Moreover, recent studies indicated at least three important roles of HGF in EGFR-TKI resistance in *EGFR* mutant lung cancer. First, HGF induces resistance to the reversible EGFR-TKIs gefitinib and erlotinib by restoring the *Met*/Gab1/PI3K/Akt pathways.^{11–13} Second, HGF accelerates expansion of preexisting *Met*-amplified cancer cells and facilitates *Met* amplification-mediated resistance during EGFR-TKI treatment.¹³ Third, after acquiring resistance to reversible EGFR-TKIs, HGF induces resistance of lung cancer cells with T790M secondary mutation to irreversible EGFR-TKIs.¹⁴ Furthermore, HGF is frequently co-expressed with T790M second mutation in *EGFR*^{13,15} and *MET* gene amplification¹³ in tumors of patients with acquired resistance to EGFR-TKIs. Consistently, although some irreversible EGFR inhibitors are in clinical development for use in patients with lung cancer refractory to gefitinib or erlotinib, the early results are disappointing.^{16,17} These findings strongly suggest that HGF is an important therapeutic target for overcoming resistance to EGFR-TKIs.

VEGF activates VEGF receptor 2 (VEGFR-2) and plays crucial roles in angiogenesis in non-small-cell lung cancer.¹⁸ HGF is also known to induce angiogenesis in cooperation with VEGF,^{19,20} which is thought to be an important therapeutic target in lung cancer.^{1,18} Therefore, we hypothesized that dual inhibition of HGF-*Met* and VEGF-VEGFR-2 may be therapeutically useful for controlling HGF-induced EGFR-TKI-resistant lung cancer. E7050 is an orally active dual TKI for *Met* and VEGFR-2.²¹ It inhibits proliferation of several *Met* gene-amplified cancer cells and tumor angiogenesis, resulting in marked tumor regression and prolongation of the lifespan of tumor-bearing mice.²¹ Based on these promising preclinical results, E7050 is currently under evaluation in clinical trials. In the present study, we determined the effect of dual inhibition of HGF-*Met* and VEGF-VEGFR-2 on HGF-induced EGFR-TKI resistance of *EGFR* mutant lung cancer cells using E7050 as well as anti-HGF Ab and anti-VEGF Ab.

Materials and Methods

Cell Culture

The *EGFR* mutant human lung adenocarcinoma cell lines PC-9¹¹ and Ma-1^{22,23} were purchased from Immuno-

Biological Laboratories Co. (Takasaki, Gunma, Japan) and were gifts from Dr. Noriyuki Masuda, Kinki Central Hospital, Sakai, Japan, respectively. Human dermal microvessel endothelial cell line (HMVEC) was purchased from Kurabo (Osaka, Japan). PC-9 and Ma-1 cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/mL of penicillin, 100 U/mL of streptomycin, and 2 mmol/L glutamine. HMVECs were maintained in HuMedia-MvG with growth supplements (Kurabo) and were used for *in vitro* assay at passages 2 to 5.

Reagents

E7050 was synthesized by Eisai Co. Ltd., Ibaraki, Japan²¹ (see Supplemental Figure S1 at <http://ajp.amjpathol.org>). Its inhibitory concentration of 50% values for *Met* in MKN45 cells with amplified *Met* and for VEGFR-2 in human umbilical vein endothelial cells (HUVECs) were 14 and 16 nmol/L, respectively. In addition, oral administration of 25 mg/kg of E7050 inhibited *Met* phosphorylation and angiogenesis in xenograft tumors.²¹ Gefitinib was obtained from AstraZeneca (Cheshire, UK). Recombinant HGF and anti-HGF Ab were prepared as reported previously.²⁴ The anti-VEGF Ab bevacizumab was obtained from Chugai Pharm (Tokyo, Japan). Recombinant VEGF, basic fibroblast growth factor, and epidermal growth factor (EGF) were obtained from R&D Systems (Minneapolis, MN).

Cell Growth Assay

Cell growth was measured using the MTT dye reduction method.²⁵ Tumor cells (2×10^3 cells/100 μ L per well) were plated into each well of 96-well plates in RPMI1640 medium with 10% FBS. After 24-hour incubation, various reagents were added to each well and were incubated for a further 72 hours. HMVECs (5×10^3 /200 μ L per well) plated in 96-well plates precoated with 1.5% gelatin were incubated in M131 medium for 24 hours. Next, the cells were washed and incubated with various reagents for 72 hours in fresh minimal essential medium containing 5% FBS. Then, 50 μ L of MTT solution (2 mg/mL; Sigma-Aldrich, St. Louis, MO) was added to all the wells, and incubation was continued for a further 2 hours. The media containing MTT solution were removed, and the dark blue crystals were dissolved by adding 100 μ L of dimethyl sulfoxide. The absorbance was measured using a microplate reader at test and reference wavelengths of 550 and 630 nm, respectively. The percentage of growth is shown relative to untreated controls. Each experiment was performed at least in triplicate, and three times independently.

Antibodies and Western Blot Analysis

Cells were lysed in cell lysis buffer containing phosphatase inhibitor cocktail and proteinase inhibitor cocktail (Sigma-Aldrich), and the protein concentrations were determined using a Bicinchoninic Acid Protein Assay Kit (Pierce Biotechnology, Rockford, IL). Total protein (40 μ g)

was resolved by SDS-PAGE (Bio-Rad Laboratories, Hercules, CA), and the proteins were then transferred onto polyvinylidene difluoride membranes (Bio-Rad Laboratories). After washing four times, membranes were incubated with Blocking One (Nacalai Tesque Inc., Kyoto, Japan) for 1 hour at room temperature and then were incubated overnight at 4°C with the following primary Abs: anti-Met (25H2), anti-phospho-Met (Y1234/Y1235) (3D7), anti-phospho-EGFR (Y1068), anti-ErbB3 (1B2), anti-phospho-ErbB3 (Tyr1289) (21D3), anti-Gab1 (#3232), phospho-Gab1 (Y627) (C32H2), anti-Akt, or phospho-Akt (Ser473) (736E11), anti-Shc1 (#2432) Abs (Cell Signaling Technology Inc., Beverly, MA) and anti-human EGFR (1 µg/mL) Ab (R&D Systems). After washing three times, membranes were incubated for 1 hour at room temperature with species-specific horseradish peroxidase-conjugated secondary Abs. Immunoreactive bands were visualized using SuperSignal west dura extended duration substrate enhanced chemiluminescent substrate (Pierce Biotechnology). Each experiment was performed at least three times independently.

Cytokine Production

Cells (2×10^5) were cultured in RPMI1640 medium with 10% FBS for 24 hours. The cells were washed with PBS and were incubated for 48 hours in 2 mL of RPMI1640 medium with 10% FBS. Then, culture medium was harvested and centrifuged, and the supernatant was stored at -70°C until analysis. The concentrations of HGF and VEGF were determined by IMMUNIS HGF enzyme immunoassay (Institute of Immunology, Tokyo, Japan) and Quantikine VEGF enzyme-linked immunosorbent assay (ELISA) (R&D Systems), respectively, according to the manufacturers' protocols. All the samples were run in duplicate. Color intensity was measured at 450 nm using a spectrophotometric plate reader. Growth factor concentrations were determined by comparison with standard curves. The detection limits for HGF and VEGF were 100 and 31 pg/mL, respectively.

HGF Gene Transfection

One day before transfection, aliquots of 1×10^5 Ma-1 cells in 1 mL of antibiotic-free medium were plated on 6-well plates. The full-length *HGF* cDNA cloned into the BCMGSneo expression vector²⁶ was transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in accordance with the manufacturer's instructions. After 24-hour incubation, the cells were washed with PBS and then were incubated for an additional 72 hours in antibiotic-containing medium. Then, the cells were selected in G418 sulfate (Calbiochem, Jolla, CA). After limiting dilution, HGF-producing cells, Ma-1/HGF, were established. HGF production by Ma-1/HGF was confirmed by ELISA.

RNA Interference Assay

Duplexed Stealth RNAi (Invitrogen) against *MET*, *ErbB3*, *Gab1*, and *Shc1* and Stealth RNAi negative control low GC duplex #3 (Invitrogen) were used for RNA interfer-

ence assay. One day before transfection, aliquots of 2×10^4 tumor cells in 400 µL of antibiotic-free medium were plated on 24-well plates. After incubation for 24 hours, the cells were transfected with small-interfering RNA (siRNA) (50 pmol) or scramble RNA using Lipofectamine 2000 (1 µL) in accordance with the manufacturer's instructions. After 24-hour incubation, the cells were washed with PBS and were incubated with or without various reagents for an additional 72 hours in antibiotic-containing medium. Cell growth was measured using a Cell Counting Kit-8 (Dojindo Molecular Technologies, Tokyo, Japan) in accordance with the manufacturer's instructions. Knockdown of *MET*, *ErbB3*, *Gab1*, and *Shc1* was confirmed by Western blot analysis. Each experiment was performed at least in triplicate and three times independently.

Xenograft Studies in Severe Combined Immunodeficiency Mice

Suspensions of Ma-1/Vec and Ma-1/HGF cells (3×10^6) were injected subcutaneously into the backs of 5-week-old female severe combined immunodeficiency (SCID) mice (Clea, Tokyo, Japan). After 7 days (tumors >5 mm in diameter), mice were randomly allocated into groups of 6 to 10 animals to receive E7050 (50 mg/kg per day) and/or gefitinib (25 mg/kg per day) by oral gavage. In some groups, anti-HGF neutralizing Ab (5 mg/kg per day) and/or anti-VEGF Ab (5 mg/kg three times a week) were injected i.p. The tumor volume was calculated ($\text{mm}^3 = \text{width}^2 \times \text{length}/2$). All the animal experiments complied with the Guidelines for the Institute for Experimental Animals, Kanazawa University Advanced Science Research Center.

Immunofluorescence for Phosphorylated VEGFR-2

To detect phosphorylated VEGFR-2 in HMVECs, HMVECs cultured on slides were rinsed with PBS and fixed in cold acetone for 5 minutes. After fixation, the slides were washed briefly in PBS and treated with 5% FBS for blocking. The slides were incubated with rabbit anti-phospho-VEGFR-2 Ab (Tyr1175, 19A10, 1:100 dilution; Cell Signaling Technology Inc.) at 4°C overnight. After washing, the slides were incubated with anti-rabbit Ab conjugated with Alexa Fluor 488 (green, 1:100 dilution; Invitrogen) and at room temperature for 40 minutes.

To detect CD31-phospho-VEGFR-2 double-positive endothelial cells, frozen sections (5 µm thick) of xenograft tumors were fixed with cold acetone and washed with PBS. After blocking with 5% normal horse serum, the slides were incubated overnight at 4°C with rabbit anti-phospho-VEGFR-2 Ab (Tyr1175) (19A10, 1:100 dilution) and rat anti-CD31 Ab (1:100 dilution; Pharmingen, San Diego, CA). After washing with PBS, the slides were stained with matched secondary Abs conjugated with Alexa Fluor 594 (red for CD31, 1:100) or Alexa Fluor 488 (green for phospho-VEGFR-2; 1:100 dilution). The localized green and red fluorescence were detected by fluorescence microscopy.

Immunohistochemical Analysis

Frozen sections (5 μm thick) of xenograft tumors were fixed with cold acetone and washed with PBS. After blocking the endogenous peroxidase activity with 3% aqueous H_2O_2 solution for 10 minutes, the sections were treated with 5% normal horse serum. The sections were then reacted with primary Ab (anti-CD31 Ab, 1:100 dilution) at 4°C overnight. After washing with PBS, anti-CD31 Ab-treated sections were incubated with peroxidase-conjugated anti-rat IgG for 40 minutes. The DAB (3,3'-diaminobenzidine tetrahydrochloride) liquid system (DakoCytomation, Glostrup, Denmark) was used to detect immunostaining. Omission of primary Ab served as a negative control.

Statistical Analysis

The statistical significance of differences was analyzed by one-way analysis of variance. In cases in which the *P* values for the overall comparisons were less than 0.05, post hoc pairwise comparisons were performed by the Newman-Keuls multiple comparison test. Statistical analyses were performed using GraphPad Prism software version 4.01 (GraphPad Software Inc., San Diego, CA).

Results

Met Inhibition Reverses Resistance to EGFR-TKIs Induced by Exogenous HGF

PC-9 and Ma-1 cells, which have an in-frame deletion in *EGFR* exon 19, were highly sensitive to gefitinib (Figure 1A).^{11,23} None of these cell lines produced detectable levels of HGF protein (Figure 2A) or expressed T790M mutation in *EGFR* or amplified *Met*. As we reported previously, exogenously added HGF induced resistance to gefitinib in PC-9 and Ma-1 cells.^{11,12} E7050, a dual TKI for Met and VEGFR-2, did not affect viability of PC-9 or Ma-1 cells at concentrations of $<1 \mu\text{mol/L}$. However, in combination with gefitinib, E7050 reversed HGF-induced resistance of PC-9 and Ma-1 cells in a dose-dependent manner (Figure 1B). These results indicated that E7050 could reverse EGFR-TKI resistance induced by exogenous HGF *in vitro*.

We next examined the effects of E7050 on signal transduction by Western blot analysis. Gefitinib inhibited the phosphorylation of EGFR and ErbB3 and, thereby, inhibited the phosphorylation of Akt and ERK1/2; however, gefitinib did not show this effect in the presence of HGF. E7050 suppressed constitutive phosphorylation of Met and its adaptor protein Gab1 but not EGFR, ErbB3, or downstream Akt and ERK1/2. HGF stimulated phosphorylation of Met and Gab1. E7050 successfully inhibited HGF-induced phosphorylation of Met and Gab1 and strongly suppressed phosphorylation of Akt combined with gefitinib (Figure 1C).




Figure 1. Met inhibition by E7050 overcomes resistance to EGFR-TKIs induced by exogenous HGF. **A:** PC-9 and Ma-1 cells were incubated with various concentrations of gefitinib with or without HGF (20 ng/mL). Cell growth was determined by MTT assay. Error bars indicate SD. **B:** PC-9 and Ma-1 cells were incubated with various concentrations of E7050 with or without HGF (20 ng/mL) and/or gefitinib (0.3 $\mu\text{mol/L}$). Cell growth was determined by MTT assay. **C:** PC-9 and Ma-1 cells were incubated with E7050 (1 $\mu\text{mol/L}$) and/or gefitinib (1 $\mu\text{mol/L}$) for 1 hour. Then, HGF (20 ng/mL) was added. Ten minutes later, cell lysates were harvested, and phosphorylation of the indicated proteins was determined by Western blot analysis. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Met Inhibition Overcomes Resistance to EGFR-TKIs Induced by Endogenous HGF

A previous study demonstrated that HGF is mainly detected in cancer cells in patients with non-small-cell lung cancer and acquired resistance to EGFR-TKIs and that transient HGF gene transfection into PC-9 cells resulted in resistance to EGFR-TKIs.¹¹ Herein, we further generated stable HGF gene transfectants (Ma-1/HGF) using Ma-1 cells to assess the role of continuously produced endogenous HGF. Ma-1/Vec were used as control cells




Figure 2. Met inhibition by E7050 overcomes resistance to EGFR-TKIs induced by endogenous HGF. **A:** Tumor cells ($1 \times 10^6/10$ mL) were incubated for 48 hours. Concentration of HGF in the culture supernatants was determined by ELISA. **B:** Ma-1/Vec and Ma-1/HGF cells were incubated with various concentrations of gefitinib with or without E7050. Cell growth was determined by MTT assay. **C:** Ma-1/HGF cells were incubated with E7050 (1 μmol/L) and/or gefitinib (1 μmol/L) for 1 hour. Then, cell lysates were harvested, and phosphorylation of the indicated proteins was determined by Western blot analysis. **D:** Ma-1/HGF cells were treated with or without scramble, *ErbB3*, *Met*, or *Gab1* siRNA for 12 hours and were further incubated in medium for 48 hours. Then, cell lysates were harvested, and expression of the indicated proteins was determined by Western blot analysis. **E:** Ma-1/HGF cells were treated with siRNA as in **D**. After 72-hour incubation in medium, cell growth was determined by MTT assay. * $P < 0.05$ versus medium alone (one-way ANOVA). Bars indicate SD.

transfected with vector alone. Ma-1/HGF, but not Ma-1 or Ma-1/Vec, secreted high levels of HGF and became resistant to gefitinib (Figure 2, A and B). Anti-HGF Ab reversed gefitinib resistance of Ma-1/HGF cells (data not shown), indicating that endogenously produced HGF induced gefitinib resistance in this cell line. E7050 combined with gefitinib successfully reversed resistance of Ma-1/HGF cells, whereas E7050 alone did not markedly inhibit the viability of Ma-1/HGF cells (Figure 2B). Gefitinib inhibited phosphorylation of EGFR and ErbB3 in Ma-1/HGF cells but did not inhibit phosphorylation of Akt. E7050 inhibited phosphorylation of Met and Gab1 and suppressed phosphorylation of Akt in combination with gefitinib (Figure 2C).

To confirm that reversal of gefitinib resistance by E7050 in Ma-1/HGF cells is due to inhibition of Met/Gab1, we conducted experiments with siRNA specific for *Met* or *Gab1*. Treatment with siRNA for *ErbB3*, *Met*, and *Gab1* successfully knocked down the corresponding protein expression (Figure 2D). Scramble or *ErbB3* siRNA did not reverse gefitinib resistance of Ma-1/HGF cells. However, siRNA for *Met* and siRNA for *Gab1* considerably sensitized Ma-1/HGF cells to gefitinib, indicating that E7050 reverses gefitinib resistance in Ma-1/HGF cells by inhibiting the Met/Gab1 pathway.

Antiangiogenic Effect of E7050 by Inhibition of VEGFR-2

We next explored the potential of E7050 against VEGFR-2. Western blot analysis indicated that HMVECs expressed VEGFR-2 protein at high levels, whereas the human *EGFR* mutant lung cancer cell lines PC-9, Ma-1, Ma-1/Vec, and Ma-1/HGF did not (Figure 3A). VEGFR-2 was phosphorylated by VEGF stimulation in HMVECs,

and E7050 showed an inhibitory effect (Figure 3, B and C). E7050 slightly inhibited constitutive viability of HMVEC cells (Figure 3D). HMVEC growth was stimulated by VEGF and basic fibroblast growth factor but not by HGF or EGF. E7050 inhibited VEGF-stimulated HMVEC growth in a dose-dependent manner (Figure 3D). E7050 was less effective against basic fibroblast growth factor-stimulated HMVEC growth. These results indicated selective activity of E7050 against VEGF-VEGFR-2.

HGF Stimulates VEGF Production by EGFR Mutant Lung Cancer Cells and E7050 Shows an Inhibitory Effect

PC-9 and Ma-1 cells constitutively produced detectable levels of VEGF, and HGF stimulated VEGF production (Figure 4A). Consistent with these observations, Ma-1/HGF cells produced higher levels of VEGF (mean \pm SD) than did Ma-1/Vec cells (2110 ± 40 versus 1170 ± 50 pg/10⁶ per 48 hours). As HGF was reported to enhance VEGF production mediated by Shc1, an adaptor protein for Met, in endothelial cells,²⁷ we next evaluated the involvement of Shc1 compared with Gab1, a common adaptor of Met, using specific siRNA. Treatment with siRNA for *Met*, *Shc1*, and *Gab1* successfully knocked down expression of the corresponding protein (Figure 2D; see also Supplemental Figure S2 at <http://ajp.amjpathol.org>). Silencing of *Met* and *Gab1*, but not *Shc1*, canceled the augmented VEGF production by HGF, indicating that HGF stimulates VEGF production by activating Met predominantly using Gab1, not Shc1, as an adaptor (Figure 4B). Moreover, E7050 successfully canceled HGF-induced VEGF production (Figure 4C). Immunoblotting with immunoprecipitation showed that




Figure 3. E7050 inhibits VEGFR-2 phosphorylation and suppresses growth of HMVECs. **A:** VEGFR-2 protein expression in HMVEC and *EGFR* mutant lung cancer cell lines was examined by Western blot analysis. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. **B:** HMVECs were cultured with or without E7050 (1 $\mu\text{mol/L}$) for 1 hour, and then 50 ng/mL of VEGF and HGF were added. After 10 minutes, the cells were lysed, and the indicated proteins were detected by immunoblotting. **C:** HMVECs were cultured with or without E7050 (1 $\mu\text{mol/L}$) for 1 hour, and then VEGF was added. After 10 minutes, the cells were fixed and stained for phosphorylated VEGFR-2. Phosphorylated VEGFR-2 was detected on the plasma membrane after VEGF stimulation. E7050 prevented expression of phosphorylated VEGFR-2 even after VEGF stimulation. **D:** HMVECs were incubated with various concentrations of E7050 for 72 hours with or without 50 ng/mL of VEGF, basic fibroblast growth factor (bFGF), HGF, or EGF. Cell growth was determined by MTT assay. Bars indicate SD.

Gab1 was constitutively associated with Met and weakly phosphorylated in Ma-1 cells. HGF remarkably augmented phosphorylation of Gab1 associated with Met (Figure 4D). Although E7050 did not affect constitutive association between Met and Gab1, it inhibited HGF-induced Gab1 phosphorylation (Figure 4D). These findings indicated that Gab1 constitutively associates with Met and mediates important signaling for not only induction of EGFR-TKI resistance but also stimulation of VEGF production.

E7050 Circumvents HGF-Induced Resistance When Combined with Gefitinib in Vivo

To investigate the therapeutic efficacy of E7050, we inoculated Ma-1/Vec or Ma-1/HGF cells into SCID mice subcutaneously. Gefitinib treatment (25 mg/kg) induced regression of tumors formed by Ma-1/Vec cells, and E7050 treatment (50 mg/kg) showed a slight inhibitory

effect (Figure 5A). Under these experimental conditions, gefitinib treatment inhibited the growth of Ma-1/HGF tumors only marginally, indicating gefitinib resistance *in vivo* caused by endogenous HGF (Figure 5B). E7050 treatment alone also retarded tumor growth, indicating mild antitumor activity of E7050 as monotherapy. However, E7050 combined with gefitinib resulted in marked growth regression of Ma-1/HGF tumors (Figure 5B).

Western blot analyses using *in vivo* tumors indicated that phosphorylation of Akt, an important survival signaling in *EGFR* mutant lung cancer, was inhibited only by combined treatment with gefitinib and E7050 in Ma-1/HGF tumors (Figure 5C; see also Supplemental Figure S3 at <http://ajp.amjpathol.org>). Histologic examinations showed that tumors produced by HGF-transfected Ma-1 (Ma-1/HGF) cells were more angiogenic than those produced by Ma-1/Vec cells (see Supplemental Figure S4 at <http://ajp.amjpathol.org>). In Ma-1/HGF tumors, wh-




Figure 4. HGF stimulates VEGF production by *EGFR* mutant lung cancer cells. **A:** PC-9 and Ma-1 cells ($2 \times 10^5/2 \text{ mL}$) were incubated with or without HGF for 48 hours. Concentration of VEGF in the culture supernatants was determined by ELISA. $*P < 0.05$ versus medium alone. Bars indicate SD. **B:** Ma-1 cells were treated with scramble, *Met*, *Gab1*, or *Shc1* siRNA for 12 hours and then were further incubated in medium for 48 hours. Then, the concentration of VEGF in the culture supernatants was determined by ELISA. $*P < 0.05$ versus si*Met*. **C:** PC-9 and Ma-1 cells ($2 \times 10^5/2 \text{ mL}$) were incubated with or without HGF (50 ng/mL) in the presence or absence of E7050 (1 $\mu\text{mol/L}$) for 48 hours. Concentration of VEGF in the culture supernatants was determined by ELISA. $*P < 0.05$ versus medium. **D:** Ma-1 cells were incubated with or without E7050 (1 $\mu\text{mol/L}$) for 1 hour and then were further incubated with or without HGF (50 ng/mL) for 10 minutes. Then, cell lysates were harvested and immunoprecipitated with the indicated antibody. Protein association was determined by Western blot analysis.




Figure 5. E7050 circumvents HGF-induced resistance *in vivo* when combined with gefitinib. **A:** Ma-1/Vec cells (3×10^6) were inoculated s.c. into SCID mice. Oral treatment with E7050 (25 or 50 mg/kg) or gefitinib (25 mg/kg) was given daily from day 7. Data shown are the mean \pm SE of six tumors. **B:** Ma-1/HGF cells (3×10^6) were inoculated s.c. into SCID mice. Oral treatment with E7050 (50 mg/kg) and/or gefitinib (25 mg/kg) was given daily from day 7. Data shown are the mean \pm SE of six tumors. **C:** Tumors harvested on day 21 were lysed and examined for phosphorylated Akt by Western blot analysis. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. **D:** Ma-1/HGF-bearing SCID mice were treated with E7050 (50 mg/kg) and/or gefitinib (25 mg/kg) for 5 days. The tumors were harvested, and frozen sections were examined for endothelial cells (CD31) and phosphorylated VEGFR-2 (pVEGFR-2) by immunostaining. **Arrowheads** indicate endothelial cells. Numbers of CD31-positive endothelial cells in a field ($\times 200$) are also shown.

areas gefitinib treatment did not affect the number of CD31-positive endothelial cells, E7050 with or without gefitinib dramatically inhibited the number of CD31-positive endothelial cells (Figure 5D; see also Supplemental Figure S5 at <http://ajp.amjpathol.org>), indicating potent antiangiogenic efficacy of E7050.

Moreover, control- or gefitinib-treated tumor contained CD31-phosphorylated VEGFR-2 double-positive cells but not in tumors treated with E7050 alone or gefitinib+E7050 (Figure 5D), indicating an association between antiangiogenic effect of E7050 and inhibition of VEGFR-2 phosphorylation *in vivo*. We also assessed the effects of gefitinib and/or E7050 on cell proliferation (Ki-67) and apoptosis (TUNEL). We found that gefitinib with or without E7050 suppressed cell proliferation in Ma-1/Vec tumors, whereas E7050 alone did not (see Supplemental Figures S5 and S6 at <http://ajp.amjpathol.org>). In Ma-1/HGF tumors, monotherapy with gefitinib or E7050 tended to reduce the number of proliferating cells, whereas combination treatment markedly inhibited cell proliferation. The number of apoptotic cells was increased in Ma-1/Vec tumors treated with gefitinib or E7050 and was markedly increased in tumors treated with both (see Supplemental Figures S5 and S7 at <http://ajp.amjpathol.org>). The number of apoptotic cells in

Ma-1/HGF tumors was increased by E7050, unaffected by gefitinib, and markedly increased by combined gefitinib and E7050. These results suggest that monotherapy with the angiogenesis inhibitor E7050 was not sufficient for regressing Ma-1/HGF tumors, whereas its combination with gefitinib, which blocks EGFR signaling, was necessary for tumor regression.

Dual Inhibition of HGF and VEGF by Specific Abs Reverses HGF-Induced Resistance When Combined with Gefitinib *In Vivo*

To confirm the effects of dual targeting of HGF/Met and VEGF/VEGFR-2 on HGF-induced resistance, we finally examined the effects of anti-HGF Ab and anti-VEGF Ab with gefitinib against Ma-1/HGF tumors *in vivo*. Anti-HGF Ab and gefitinib slightly inhibited the growth of Ma-1/HGF tumors (Figure 6A). However, combined use of anti-HGF Ab and gefitinib further inhibited the growth, suggesting that anti-HGF Ab neutralized HGF and resensitized Ma-1/HGF cells to gefitinib *in vivo* (Figure 6A). In a parallel experiment, monotherapy with anti-VEGF Ab or combined treatment with anti-HGF Ab and anti-VEGF Ab inhibited tumor growth as effectively as com-




Figure 6. Dual inhibition of HGF and VEGF by specific antibodies reversed HGF-induced resistance when combined with gefitinib *in vivo*. **A:** Ma-1/HGF cells (3×10^6) were inoculated subcutaneously into SCID mice. From day 7, oral daily treatment with gefitinib (25 mg/kg), i.p. daily treatment with anti-HGF Ab (5 mg/kg per day), and/or i.p. treatment with anti-VEGF Ab (5 mg/kg per day, three times a week), were given. Data shown are the mean \pm SE of six tumors on day 17. * $P < 0.05$. Bars indicate SD. **B:** Scheme showing the role of HGF in *EGFR* mutant lung cancer cells. HGF induces EGFR-TKI resistance and VEGF production by activating the Met/Gab1 axis.

combined treatment with anti-HGF Ab and gefitinib in this model. The addition of gefitinib to anti-VEGF Ab further inhibited growth. Combined use of anti-HGF Ab, anti-VEGF Ab, and gefitinib showed the strongest inhibitory effect on the growth of Ma-1/HGF tumors, indicating the usefulness of dual inhibition of HGF and VEGF for overcoming HGF-induced resistance to EGFR-TKIs (Figure 6A). This was further supported by results of histologic analysis with Ma-1/HGF tumors. Anti-HGF Ab tended to decrease the number of proliferating tumor cells and tumor vessels and increase the number of apoptotic cells (see Supplemental Figures S5–S8 at <http://ajp.amjpathol.org>). Anti-HGF Ab with gefitinib discernibly reduced proliferating cell numbers, tumor vessel numbers, and phosphorylation of Akt and increased apoptotic cell numbers, but their effects were less than those of E7050 (dual inhibitor of HGF/Met and VEGFR-2) with gefitinib.

Discussion

HGF is a mediator that regulates multiple biological functions, including cell motility, invasion, and angiogenesis.²⁸ Moreover, recent studies indicated considerable roles of HGF on sensitivity to anticancer agents. For example, HGF was reported to induce cisplatin resistance in lung adenocarcinoma cells by reducing the expression of apoptosis-inducing factor.²⁹ It inhibited Fas-induced apoptosis by activating the PI3K/Akt pathway and, thus, inhibiting Fas death-inducing signaling complex formation in hepatocellular carcinoma.³⁰ HGF also suppressed anoikis by increasing cyclooxygenase-2 expression through activation of Erk and AP-1 in head and neck squamous cell carcinoma.³¹ Regarding sensitivity to molecularly targeted drugs, we demonstrated that HGF induces EGFR-TKI resistance in *EGFR* mutant lung cancer.¹¹ Thus, accumulating evidence suggests that HGF is an ideal therapeutic target for drug resistance in various types of cancer.

In the present study, we found that HGF stimulates VEGF production of *EGFR* mutant lung cancer cells by predominantly activating the Met/Gab1 axis in the same way as induction of EGFR-TKI resistance (Figure 6B). Moreover, the present findings using mainly E7050, a dual inhibitor of Met and VEGFR-2 kinases, indicated the rationale of dual inhibition of the HGF-Met axis and the VEGF-VEGFR-2 axis on treatment of HGF-induced EGFR-TKI resistance in *EGFR* mutant lung cancer. This strategy was supported by recent studies indicating that blockade of VEGFR signaling caused hypoxia by inhibition of angiogenesis and that hypoxia is likely to enhance HGF-Met signaling and, thereby, promote tumor survival and metastasis. In fact, in renal cell carcinoma, HGF was reported to induce resistance to sunitinib, an inhibitor of multiple kinases, including VEGFR-2, by compensating for inhibited angiogenesis.³² In a model of pancreatic neuroendocrine cancer, inhibition of VEGFR caused shrinkage of the primary tumor, but it also made the surviving cancer more aggressive with more metastatic behavior.³³ Clinical studies indicated a correlation between the presence of hypoxic regions in neoplastic lesions and poor prognosis.³⁴ Hypoxic conditions induced transcriptional activation of Met and subsequent amplification of HGF-Met signaling, thereby increasing the invasiveness of cancer cells.³⁵ Therefore, dual blockade of the HGF-Met and VEGF-VEGFR axes may be valuable for overcoming not only EGFR-TKI resistance but also angiogenesis inhibitor resistance.

In endothelial cells, HGF was reported to induce VEGF production using Shc1 as an adaptor for Met.²⁷ In contrast, silencing of *Shc1* did not abrogate HGF-induced VEGF production in *EGFR* mutant lung cancer cells, although similar to Gab1, Shc1 constitutively associated with Met, as well as with Gab1. On the other hand, Gab1 is thought to be an important adaptor protein for Met-mediated signaling in various cell types. The present data show that Gab1 constitutively associated with Met and HGF markedly stimulated phosphorylation of Gab1 in *EGFR* mutant lung cancer cells. Silencing of Gab1 successfully canceled HGF-stimulated VEGF production and

HGF-induced EGFR-TKI resistance. These findings suggest that Gab1 may be a novel ideal target for controlling EGFR mutant lung cancer.

These data suggest that E7050 regressed tumors with HGF-induced resistance by several mechanisms. First, E7050 inhibited phosphorylation of Met expressed in cancer cells, blocked the downstream Gab1/PI3K/Akt pathway, and, hence, resensitized the cancer cells. Second, E7050 inhibited HGF-induced VEGF production by cancer cells and may indirectly suppress angiogenesis. Third, E7050 inhibited phosphorylation of VEGFR-2 in endothelial cells and directly suppressed angiogenesis. VEGF inhibition was suggested to normalize tumor vascular structure and permeability, decrease tumor interstitial pressure, and increase penetration of anticancer drugs into tumors.³⁶ Therefore, it is also possible that E7050 increased its own penetration into tumors by inhibiting VEGFR-2 phosphorylation and normalizing tumor vascular structure and permeability. Recently, neuropilin-1, the co-receptor for VEGF165 isoform, was reported to associate with Met and to mediate VEGF-triggered expression of myeloid cell leukemia-1, a member of the Bcl-2 family, which inhibits cell apoptosis, in prostate cancer cells.³⁷ In Ma-1/HGF tumors, E7050 treatment decreased the expression of myeloid cell leukemia-1 and survivin, another member of the Bcl family (see Supplemental Figure S9 at <http://ajp.amjpathol.org>). Thus, E7050 might also inhibit VEGF/neuropilin-triggered antiapoptotic protein expression by suppressing Met phosphorylation.

A recent study indicated an interaction between HGF and *Met* amplification in EGFR-TKI resistance in lung cancer. In the presence of gefitinib, continuous exposure to HGF accelerates expansion of preexisting *MET*-amplified cancer cells, although this was observed only in HCC827 cells.¹³ We established Ma-1 cells (Ma-1/HGF) constitutively producing HGF by *HGF* gene transfection. However, Ma-1/HGF did not show *Met* amplification (data not shown). Therefore, this phenomenon may be uniquely observed in a population of EGFR mutant lung cancer cells.

It is important to define the incidence rate of HGF-induced resistance to EGFR-TKI in EGFR mutant lung cancer. In a previous study with 10 clinical specimens of EGFR mutant lung cancer, we reported the presence of patients whose resistance was associated with high HGF expression but not EGFR-T790M second mutation or *Met* amplification.¹¹ This was confirmed by another group.¹³ Moreover, it was reported that HGF is frequently co-expressed in tumors with EGFR-T790M secondary mutation or *Met* amplification.^{13,15} Although there are considerable ethnic differences in the incidence rates of EGFR mutation in lung cancer,³⁸ it is still unclear whether there are ethnic differences in the incidence of resistance mechanisms, such as EGFR-T790M secondary mutation, *Met* amplification, and HGF overexpression. We are currently engaged in a multicenter trial to elucidate the incidence of HGF-induced EGFR-TKI resistance and the involvement of angiogenesis in a Japanese cohort. Recent studies indicated that blood levels of HGF and/or VEGF are associated with clinical response to EGFR-TKIs in

patients with lung cancer,^{39–41} suggesting key roles of HGF and VEGF and the possibility of noninvasive diagnosis of HGF-induced resistance to EGFR-TKIs.

In conclusion, we provided preclinical evidence showing the rationale of dual inhibition of HGF-Met and VEGF-VEGFR-2 in HGF-induced EGFR-TKI resistance of EGFR mutant lung cancer. Further studies are needed to determine whether dual targeting therapy will be clinically effective in patients with EGFR mutant lung cancer who develop HGF-induced resistance.

Acknowledgment

We thank Dr. Naofumi Mukaida (Cancer Research Institute, Kanazawa University, Kanazawa, Japan) for providing BCMGSneo plasmid.

References

1. Herbst RS, Heymach JV, Lippman SM: Lung cancer. *N Engl J Med* 2008, 359:1367–1380
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004, 350:2129–2139
3. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004, 304:1497–1500
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006, 355:2542–2550
5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoaka M: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010, 11:121–128
6. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010, 362:2380–2388
7. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *J Clin Oncol* 2010, 28:357–360
8. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Koehler O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halms B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2005, 352:786–792
9. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005, 2:e73
10. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 2007, 316:1039–1043
11. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi

- T, Yatabe Y, Nakamura T, Sone S: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations. *Cancer Res* 2008, 68:9479–9487
12. Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S: Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. *Clin Cancer Res* 2009, 15:6630–6638
 13. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. *Cancer Cell* 2010, 17:77–88
 14. Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S: Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. *Clin Cancer Res* 2010, 16:174–183
 15. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K: Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. *Lung Cancer* 2010, 68:198–203
 16. Miller VA, Hirsh V, Cadranet J, Chen Y-M, Park K, Kim SW, Caicun Z, Oberdick M, Shahidi M, Yang CH: Phase IIb/III double-blind randomized trial of afatinib (BIBW2992, and irreversible inhibitor of EGFR/HER1 and Her2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1) (abstract LBA1). *Ann Oncol* 2010, 21:viii1
 17. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2010, 28:3076–3083
 18. Keedy VL, Sandler AB: Inhibition of angiogenesis in the treatment of non-small cell lung cancer. *Cancer Sci* 2007, 98:1825–1830
 19. Dong G, Lee TL, Yeh NT, Geoghegan J, Waes CV, Chen Z: Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor. *Oncogene* 2004, 23:6199–6208
 20. Van Belle E, Witzensbichler B, Chen D, Silver M, Chang L, Schwall R, Isner JM: Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. *Circulation* 1998, 97:381–390
 21. Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S, Shirotori S, Asada M, Obaishi H: E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. *Cancer Sci* 2010, 101:210–215
 22. Masuda N, Fukuoka M, Matsui K, Kusunoki Y, Kudoh S, Negoro S, Takifuji N, Fujisue M, Morino H, Nakagawa K, Nishioka M, Takada M: Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer. *J Natl Cancer Inst* 1991, 83:1743–1748
 23. Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, Takada M, Fukuoka M, Nakagawa K: Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. *Cancer Res* 2007, 67:2046–2053
 24. Montesano R, Matsumoto K, Nakamura T, Orci L: Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. *Cell* 1991, 67:901–908
 25. Green LM, Reade JL, Ware CF: Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. *J Immunol Methods* 1984, 70:257–268
 26. Nishioka Y, Yano S, Fujiki F, Mukaida N, Matsushima K, Tsuruo T, Sone S: Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance. *Int J Cancer* 1997, 71:170–177
 27. Saucier C, Khoury H, Lai KM, Peschard P, Dankort D, Naujokas MA, Holash J, Yancopoulos GD, Muller WJ, Pawson T, Park M: The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. *Proc Natl Acad Sci U S A* 2004, 101:2345–2350
 28. Matsumoto K, Nakamura T: Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. *Int J Cancer* 2006, 119:477–483
 29. Chen JT, Huang CY, Chiang YY, Chen WH, Chiou SH, Chen CY, Chow KC: HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells. *Am J Respir Cell Mol Biol* 2008, 38:559–565
 30. Hayashida M, Kawano H, Nakano T, Shiraki K, Suzuki A: Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. *Hepatology* 2000, 32:796–802
 31. Zeng Q, McCauley LK, Wang CY: Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2: implication in head and neck squamous cell carcinoma progression. *J Biol Chem* 2002, 277:50137–50142
 32. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG: HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. *Cancer Res* 2010, 70:10090–10100
 33. Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. *Cancer Cell* 2005, 8:299–309
 34. Höckel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. *J Natl Cancer Inst* 2001, 93:266–276
 35. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. *Cancer Cell* 2003, 3:347–361
 36. Jain RK: Molecular regulation of vessel maturation. *Nat Med* 2003, 9:685–693
 37. Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, Chen Z, Wang R, Marshall FF, Chung LW, Wu D: Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. *Mol Cancer* 2010, 9:9
 38. Mitsudomi T, Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. *Cancer Sci* 2007, 98:1817–1824
 39. Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, Sone T, Horiike A, Nishio M, Ohira T, Ikeda N, Yamanaka T, Saijo N, Nishio K: Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. *Clin Cancer Res* 2010, 16:4616–4624
 40. Tanaka H, Kimura T, Kudoh S, Mitsuoaka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K: Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. *Int J Cancer* 2011, 129:1410–1416
 41. Han JY, Kim JY, Lee SH, Yoo NJ, Choi BG: Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. *Lung Cancer* 2011, 74:293–299

Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells

Tadaaki Yamada¹, Shinji Takeuchi¹, Junya Nakade¹, Kenji Kita¹, Takayuki Nakagawa^{1,2}, Shigeki Nanjo¹, Takahiro Nakamura³, Kunio Matsumoto³, Manabu Soda⁴, Hiroyuki Mano⁴, Toshimitsu Uenaka², and Seiji Yano¹

Abstract

Purpose: Cancer cell microenvironments, including host cells, can critically affect cancer cell behaviors, including drug sensitivity. Although crizotinib, a dual tyrosine kinase inhibitor (TKI) of ALK and Met, shows dramatic effect against *EML4-ALK* lung cancer cells, these cells can acquire resistance to crizotinib by several mechanisms, including ALK amplification and gatekeeper mutation. We determined whether microenvironmental factors trigger ALK inhibitor resistance in *EML4-ALK* lung cancer cells.

Experimental Design: We tested the effects of ligands produced by endothelial cells and fibroblasts, and the cells themselves, on the susceptibility of *EML4-ALK* lung cancer cell lines to crizotinib and TAE684, a selective ALK inhibitor active against cells with ALK amplification and gatekeeper mutations, both *in vitro* and *in vivo*.

Results: *EML4-ALK* lung cancer cells were highly sensitive to ALK inhibitors. EGF receptor (EGFR) ligands, such as EGF, TGF- α , and HB-EGF, activated EGFR and triggered resistance to crizotinib and TAE684 by transducing bypass survival signaling through Erk1/2 and Akt. Hepatocyte growth factor (HGF) activated Met/Gab1 and triggered resistance to TAE684, but not crizotinib, which inhibits Met. Endothelial cells and fibroblasts, which produce the EGFR ligands and HGF, respectively, decreased the sensitivity of *EML4-ALK* lung cancer cells to crizotinib and TAE684, respectively. EGFR-TKIs resensitized these cells to crizotinib and Met-TKI to TAE684 even in the presence of EGFR ligands and HGF, respectively.

Conclusions: Paracrine receptor activation by ligands from the microenvironment may trigger resistance to ALK inhibitors in *EML4-ALK* lung cancer cells, suggesting that receptor ligands from microenvironment may be additional targets during treatment with ALK inhibitors. *Clin Cancer Res*; 18(13); 3592–602. ©2012 AACR.

Introduction

ALK fusion with *EML4* in non-small cell lung cancer (NSCLC) was first detected in 2007 (1), with 3% to 7% of unselected NSCLCs having this fusion gene (1–4). *EML4-ALK* lung cancer is more frequently observed in patients with adenocarcinoma than with other histologies, in young adults than in older patients, and in never-smokers or light

smokers (<15 pack-years) than in heavier smokers (2, 3). ALK kinase inhibitors show dramatic effects against lung cancers with *EMK4-ALK* *in vitro* and *in vivo* (3, 4). In a phase I–II trial with crizotinib, a dual tyrosine kinase inhibitor (TKI) of ALK and Met, the overall response rate was 47 of 82 (57%) patients with *EML4-ALK*-positive tumors (5). However, almost all patients who show a marked response to ALK-TKIs acquire resistance to these agents after varying periods of time (6, 7). Secondary mutations, including the gatekeeper L1196M mutation and others (F1174L, C1156Y, G1202R, S1206Y, 1151-T-ins, and G1269A), ALK amplification, *KIT* amplification, and autophosphorylation of EGF receptor (EGFR), were shown to be responsible for acquired resistance to crizotinib in ALK-translocated cancers (6–10).

Selective ALK inhibitors, including TAE684 and CH5424802, have been reported active against *EML4-ALK* lung cancer cells with ALK amplification and secondary mutations. These cells, however, may develop resistance to this class of inhibitor, due to several mechanisms, including novel ALK mutations (L1152R, L1198P, and D1203N), coactivation of EGFR and ErbB2, and EGFR phosphorylation (3, 11, 12).

Authors' Affiliations: ¹Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa; ²Tsukuba Research Laboratories, Eisai co., Ltd., Ibaraki; ³Division of Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa; and ⁴Division of Functional Genomics, Jichi Medical University, Shimotsuke, Tochigi, Japan

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corresponding Author: Seiji Yano, Division of Medical Oncology, Cancer Research Institute, Kanazawa University 13-1, Takara-machi, Kanazawa, Ishikawa 920-0934, Japan. Phone: 81-76-265-2794; Fax: 81-76-234-4524; E-mail: syano@staff.kanazawa-u.ac.jp

doi: 10.1158/1078-0432.CCR-11-2972

©2012 American Association for Cancer Research.

Translational Relevance

Although crizotinib, a dual inhibitor of ALK and Met, shows dramatic effects against *EML4-ALK* lung cancer cells, these cells can acquire resistance by several mechanisms, including ALK amplification and gatekeeper mutation. Selective ALK inhibitors may overcome crizotinib resistance due to these mechanisms, but these cells may become resistant to these inhibitors.

We show here that EGF receptor ligands produced by endothelial cells can cause *EML4-ALK* lung cancer cells to become resistant to crizotinib and selective ALK inhibitors by triggering bypass survival signals. By contrast, hepatocyte growth factor produced by fibroblasts can induce resistance to selective ALK inhibitors, but not crizotinib. Because endothelial cells and fibroblasts are components of the microenvironment, our findings raise clinical questions about the class of ALK inhibitors more beneficial for *EML4-ALK* lung cancer patients. Moreover, our results provide a rationale for targeting receptor ligands in the microenvironment for more successful treatment with ALK inhibitors.

Most human cancers are composed of cancer cells that coexist with a variety of extracellular matrix components and cell types, including fibroblasts, endothelial cells, and immune cells, which collectively form the tumor microenvironment (13). This microenvironment can influence the growth, survival, invasiveness, metastatic ability, and drug sensitivity of cancer cells within these tumors (14). Paracrine signaling between cancer cells and host cells in the microenvironment, mediated by cytokines, chemokines, growth factors, and other signaling molecules, plays a critical role in tumor growth (15). As receptors for these factors, the EGFR family of receptors and Met are of particular interest in lung cancer (16). The EGFR family consists of at least 4 receptor tyrosine kinases, including EGFR (ErbB1), Her2/neu (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). To date, 7 ligands for EGFR have been identified: EGF, TGF- α ; heparin-binding EGF-like growth factor (HB-EGF); amphiregulin; betacellulin; epiregulin; and epigen (17). By contrast, Met is the only specific receptor for hepatocyte growth factor (HGF) and HGF binds only to Met (18). Many lung cancer cells express EGFR and Met, with these cells and others in their microenvironment expressing their ligands (19, 20), suggesting that these receptors and ligands modulate the sensitivity of cancer cells to molecular targeted drugs in their microenvironment. We previously showed that fibroblast-derived HGF induces EGFR-TKI resistance in *EGFR*-mutant lung cancer cells by activating Met and downstream pathways (21, 22). However, the role of the microenvironment in the sensitivity of *EML4-ALK* lung cancer cells to ALK-TKIs has not been determined. We therefore examined whether factors in the microenvironment of *EML4-ALK* lung cancer cells trigger their resistance to crizotinib and TAE684, a selective ALK

inhibitor, as well as clarifying their underlying mechanisms of action.

Materials and Methods

Cell culture

The H2228 human lung adenocarcinoma cell line, with the *EML4-ALK* fusion protein variant3 (E6;A20), the umbilical vein endothelial cell line human umbilical vein endothelial cells (HUVEC) and the human bronchial epithelial cell line BEAS-2B, transformed with SV40 virus, were purchased from the American Type Culture Collection. The H3122 human lung adenocarcinoma cell line, with the *EML4-ALK* fusion protein variant1 (E13;A20), was kindly provided by Dr. Jeffrey A. Engelman of the Massachusetts General Hospital Cancer Center, Boston, MA (3). The MANA2 mouse lung adenocarcinoma cell line was established in Jichi Medical University from a tumor nodule developed in a transgenic mouse expressing *EML4-ALK* variant 1 (E13;A20) (23). The MRC-5 and IMR-90 lung embryonic fibroblast cell lines were obtained from RIKEN Cell Bank. The human dermal microvessel endothelial cell line HMVEC was purchased from Kurabo. The monocytic leukemia cell line U937 was purchased from Health Science Research Resources Bank. H2228 cells were cultured in RPMI-1640 medium, MANA2 cells were cultured in DMEM/F12+GlutaMAX-1, and MRC-5 (P25–30) cells were cultured in Dulbecco's modified Eagle's medium (DMEM) medium, supplemented with 5% fetal bovine serum, penicillin (100 U/mL), and streptomycin (50 μ g/mL), in a humidified CO₂ incubator at 37°C. HMVECs and HUVECs were maintained in HuMedia-MvG with growth supplements (Kurabo) and used for *in vitro* assays at passages 2 to 5 and 2 to 4, respectively. BEAS-2B cells were maintained in LHC9/RPMI-1640 medium, as described (24), and used for *in vitro* assays at passages 42 to 46. Macrophage differentiation of U937 cells was induced by incubation in RPMI-1640 medium containing 10 ng/mL phorbol 12-myristate 13-acetate (Sigma Chemical Co.; ref. 25) for 5 days, with floating cells removed by rinsing with PBS, as described (26). Differentiated U937 cells (PMA-U937 cells) attached to the dishes were used for *in vitro* assays at passages 6 to 8. All cells were passaged for less than 3 months before renewal from frozen, early-passage stocks obtained from the indicated sources. Cells were regularly screened for *Mycoplasma* using a MycoAlert *Mycoplasma* Detection Kit (Lonza).

Reagents

TAE684, crizotinib, and WZ4002 were purchased from Selleck Chemicals. Erlotinib hydrochloride was obtained from Chugai Pharmaceutical Co., Ltd. The anti-human EGFR antibody cetuximab was obtained from Merck Serono. E7050 was synthesized by Eizai Co., Ltd. (27). Goat anti-human HGF antibody, control goat IgG, recombinant EGF, TGF- α , HB-EGF, IGF-1, and PDGF-AA were purchased from R&D Systems. Recombinant HGF was prepared as described (28).

Cell growth assay

Cell proliferation was measured using the MTT dye reduction method (17). Tumor cells at 80% confluence were harvested, seeded at 2×10^3 cells per well in 96-well plates, and incubated in appropriate medium for 24 hours. Several concentrations of TAE684, crizotinib, erlotinib, WZ4002, E7050, cetuximab, anti-HGF antibody, and/or EGF, TGF- α , HB-EGF, IGF-1, PDGF-AA, and HGF were added to each well, and incubation was continued for a further 72 hours. To each well was added 50 μ L MTT (2 mg/mL; Sigma), followed by incubation for 2 hours at 37°C. The media were removed and the dark blue crystals in each well were dissolved in 100 μ L of dimethyl sulfoxide (DMSO). Absorbance was measured with an MTP-120 Microplate reader (Corona Electric) at test and reference wavelengths of 550 and 630 nm, respectively. The percentage growth was calculated relative to untreated controls. Each assay was carried out at least in triplicate, with results based on 3 independent experiments.

Apoptosis assay

H2228 and H3122 cells (3×10^3 cells) were seeded in 96-well, white-walled plates and incubated overnight. The cells were treated with crizotinib (1 μ mol/L) or vehicle (DMSO) for 48 hours. Cellular apoptosis was determined by measuring caspase-3/7 activity using a luminometric Caspase-Glo 3/7 assay (Promega) according to the manufacturer's protocol, with luminescence intensity measured using a Fluoroskan Ascent FL plate reader (Thermo Scientific). Cellular apoptosis was expressed relative to DMSO-treated control cells.

RNA interference

Duplexed Stealth RNAi (Invitrogen) against *EGFR*, *Met*, *ErbB3*, *Gab1*, *ALK*, and Stealth RNAi-negative control low GC Duplex #3 (Invitrogen) were used for RNA interference (RNAi) assays. Briefly, aliquots of 1×10^5 cells in 2 mL of antibiotic-free medium were plated into each well of a 6-well plate and incubated at 37°C for 24 hours. The cells were transfected with siRNA (250 pmol) or scrambled RNA using Lipofectamine 2000 (5 μ L) in accordance with the manufacturer's instructions (Invitrogen). After 24 hours, the cells were washed twice with PBS and incubated with or without crizotinib (100 nmol/L), TAE684 (100 nmol/L), recombinant human EGF (100 ng/mL), TGF- α (100 ng/mL), HB-EGF (10 ng/mL), or HGF (50 ng/mL) for an additional 48 hours in antibiotic-containing medium. These tumor cells were then used for cell proliferation assays, with *EGFR*, *Met*, *ErbB3*, *Gab1*, and *ALK* knockdowns (#1, #2) confirmed by Western blotting.

The siRNA target sequences were as follows: *EGFR*, 5'-CGGAATAGGTATTGGTGAATTTAAA-3' and 5'-UUUAAA-UUCACCAAUACCUAUUCCG-3', *Met*, 5'-UCCAGAAGAU-CAGUUUCCUAAUUA-3' and 5'-UGAAUUAGGAAACU-GAUCUUCUGGA-3', *ErbB3*, 5'-GGCCAUGAAUGAAUU-CUCUACUCUA-3' and 5'-UAGAGUAGAGAAUUCAUU-CAUGGCC-3', *Gab1*, 5'-UAGAGUAGCAGAGGAUGAAU-CUGCC-3' and 5'-GGCAGAUUCAUCCUCUGCUACUC-

UA-3', *ALK* #1, 5'-UCAUUUAUCCGGUUAUACAGGCCCA-GG-3' and 5'-CCUGGGCCUGUAUACCGGAUAAUGA-3', and *ALK* #2, 5'-AAAGCUGCACUCCAGACCAUUAUCGG-3' and 5'-CCGAUAUGGUCUGGAGUGCAGCUUU-3'. Each assay was carried out at least in triplicate, with 3 independent experiments conducted.

Western blotting

SDS polyacrylamide gels (Bio-Rad) were loaded with 40 μ g total protein per lane; following electrophoresis, the proteins were transferred onto polyvinylidene difluoride membranes (Bio-Rad), which were incubated with Blocking One (Nacalai Tesque) for 1 hour at room temperature, followed by overnight incubation at 4°C with anti-*ALK* (C26G7), anti-phospho-*ALK* (Tyr1604), anti-phospho-*EGFR* (Tyr1068), anti-*STAT-3* (79D7), anti-phospho-*STAT-3* (Y705), anti-Akt, anti-phospho-Akt (Ser473), anti-ErbB4 (111B2), anti-phospho-ErbB4 (Tyr1284), anti-Met (25H2), anti-phospho-Met (Y1234/Y1235) (3D7), anti-Gab1 (#3232), anti-phospho-Gab1 (Tyr627) (C32H2), anti-ErbB3 (1B2), anti-phospho-ErbB3 (Tyr1289) (21D3), or anti- β -actin (13E5) antibodies (1:1,000 dilution each; Cell Signaling Technology), or with anti-human *EGFR* (1 μ g/mL), anti-human/mouse/rat extracellular signal-regulated kinase (Erk)1/Erk2 (0.2 μ g/mL), or anti-phospho-Erk1/Erk2 (T202/Y204) (0.1 μ g/mL) antibodies (R&D Systems). After washing 3 times, the membranes were incubated for 1 hour at room temperature with secondary Ab (horseradish peroxidase-conjugated species-specific Ab). Immunoreactive bands were visualized with SuperSignal West Dura Extended Duration Substrate Enhanced Chemiluminescent Substrate (Pierce). Each experiment was carried out at least 3 times independently.

HGF, EGF, TGF- α , and HB-EGF production in cell culture supernatant

Cells (2×10^5) were cultured in 2 mL of RPMI-1640 or DMEM with 5% FBS for 24 hours. The cells were washed with PBS and incubated for 48 hours in RPMI-1640 or DMEM with 5% FBS. The culture medium was harvested and centrifuged, and the supernatant was stored at -70°C until analysis. HGF (Immunis HGF EIA; B-Bridge International), EGF, TGF- α , and HB-EGF (Quantikine ELISA kits; R&D Systems) were assayed by ELISA, in accordance with the manufacturer's procedures. All samples were run in triplicate. Color intensity was measured at 450 nm with a spectrophotometric plate reader. Growth factor concentrations were determined by comparison with standard curves. The detection limits for HGF, EGF, TGF- α , and HB-EGF were 0.1 ng/mL, 3.9 pg/mL, 15.6 pg/mL, and 31.2 pg/mL, respectively.

Coculture of lung cancer cells with fibroblasts or endothelial cells

Cells were cocultured in Transwell Collagen-Coated chambers separated by an 8- μ m (BD Biosciences, Erembodegem) or 3- μ m (Corning Costar) pore size filter. Tumor cells (8×10^3 cells/800 μ L) with or without TAE684

(100 nmol/L) or crizotinib (100 nmol/L) in the lower chamber were cocultured with MRC-5 (1×10^4 cells/300 μ L) or HMVEC (1×10^4 cells/300 μ L) cells, with or without 2 hours of pretreatment with anti-human HGF antibody (2 μ g/mL) or cetuximab (2 μ g/mL) in the upper chamber for 72 hours. The upper chamber was then removed, 200 μ L of MTT solution (2 mg/mL; Sigma) was added to each well and the cells were incubated for 2 hours at 37°C. The media were removed and the dark blue crystals in each well were dissolved in 400 μ L of DMSO. Absorbance was measured with an MTP-120 Microplate reader (Corona Electric) at test and reference wavelengths of 550 and 630 nm, respectively. The percentage growth was measured relative to untreated controls. All samples were assayed at least in triplicate, with each experiment conducted 3 times independently.

Xenograft studies in SCID mice

Suspensions of H2228 cells (5×10^6), with or without MRC-5 cells (5×10^6), were injected subcutaneously into the backs of 5-week-old male severe combined immunodeficient (SCID) mice (Japan Clea). After 4 days (tumors diameter >4 mm), mice were randomly allocated into groups of 6 animals to receive TAE684 (1.25 mg/kg/d) or vehicle by oral gavage. Tumor size was measured with digital calipers, and tumor volume was calculated as $0.5 \times \text{length} \times (\text{width})^2$. All animal experiments complied with the Guidelines for the Institute for Experimental Animals, Kanazawa University Advanced Science Research Center (approval no. AP-081088).

HGF production in tumor tissues

Tumors obtained from SCID mice after 4 and 8 days were lysed in mammalian tissue lysis buffer containing a phosphatase and proteinase inhibitor cocktail (Sigma). HGF was quantitated by ELISA (Immunis HGF EIA; Institute of Immunology), with a detection limit of 0.1 ng/mL. All samples were assayed in triplicate.

Statistical analysis

Differences were analyzed by one-way ANOVA. All statistical analyses were carried out using GraphPad Prism Ver. 4.01 (GraphPad Software, Inc.). $P < 0.05$ was considered significant.

Results

HGF and/or EGFR ligands reduced the sensitivity of EML4-ALK lung cancer cells to ALK inhibitor *in vitro*

We first examined the sensitivity of human H2228, human H3122, and mouse MANA2 lung cancer cell lines, all containing EML4-ALK translocations, to the ALK inhibitors crizotinib and TAE684, and to various EGFR-TKIs. Human H2228 cells with EML4-ALK variant 3 (E6;A20) and H3122 cells with EML4-ALK variant 1 (E13;A20) were insensitive to the EGFR-TKIs erlotinib (a reversible EGFR-TKI) and WZ4002 (selective for mutant EGFR), but sensitive to the ALK-TKIs crizotinib and TAE684 (Fig. 1). MANA2 cells, established from lung tumors of an EML4-ALK variant




Figure 1. EML4-ALK lung cancer cells are highly sensitive to the ALK inhibitors, crizotinib, and TAE684. The sensitivity of EML4-ALK lung cancer cells, human H2228, human H3122, and mouse MANA2, to the ALK inhibitors, crizotinib, and TAE684 were determined by analyzing the effects of the EGFR-TKIs, erlotinib (reversible EGFR-TKI), and WZ4002 (mutant EGFR selective TKI). Tumor cell growth after 72 hours was measured by the MTT assay. Each sample was assayed in triplicate, with each experiment repeated at least 3 times independently.

1 (E13;A20) transgenic mouse, were also sensitive to crizotinib and TAE684, although their viability was slightly inhibited by high concentrations (1 μ mol/L) of EGFR-TKIs.

Because several growth factors have been associated with poor patient prognosis and/or drug resistance in lung cancer, we explored the effect of EGFR ligands (EGF, TGF- α , and HB-EGF), IGF-1, PDGF-AA, and HGF on the sensitivity of EML4-ALK lung cancer cells to ALK inhibitors. In the absence of ALK inhibitors, these growth factors slightly increased the viability of H2228, H3122, and MANA2 cells. In H2228 cells, all 3 EGFR ligands reduced sensitivity to crizotinib in a dose-dependent manner, but IGF-1, PDGF-AA, and HGF failed to do so (Fig. 2, Supplementary Fig. S1). Interestingly, HGF, as well as the EGFR ligands, reduced sensitivity to TAE684, but IGF-1 and PDGF-AA failed to do so. Similar results were observed in H3122 and MANA2 cells. To further confirm the effect of these growth factors on specific ALK inhibition, we knocked down ALK using 2 different specific siRNAs in H2228 cells. Whereas H2228 cells were highly sensitive to ALK-specific siRNAs, EGFR ligands and HGF restored cell viability inhibited by ALK knockdown (Supplementary Fig. S2). When we




Figure 2. HGF and/or EGFR ligands (EGF, TGF- α , and HB-EGF) reduce the sensitivity of EML4-ALK lung cancer cells to ALK inhibitors *in vitro*. H2228, H3122, and MANA2 cells were incubated with or without crizotinib (100 nmol/L), TAE684 (100 nmol/L), and/or EGF, TGF- α , IGF-1, or PDGF-AA (100 ng/mL); HB-EGF (10 ng/mL), or HGF (50 ng/mL), with cell growth determined after 72 hours. The percentage growth is shown relative to untreated controls. Each sample was assayed in triplicate, with each experiment repeated at least 3 times independently.

assessed the ability of crizotinib to induce apoptosis in H2228 and H3122 cells, we found that crizotinib induced apoptosis in H3122, but not H2228, cells (Supplementary Fig. S3).

HGF and EGFR ligands trigger ALK inhibitor resistance via Met and EGFR, respectively

To assess the mechanism by which these growth factors reduced cell sensitivity to ALK inhibitors, we analyzed the phosphorylation status of ALK, receptors, and their downstream molecules in H2228, H3122, and MANA2 cells by Western blotting. Crizotinib inhibited ALK phosphorylation, thereby suppressing the phosphorylation of Akt, Erk1/2 and STAT-3, as described (ref. 11; Fig. 3A, Supplementary Fig. S4). The EGFR ligands, EGF, TGF- α , and HB-EGF stimulated EGFR phosphorylation. Crizotinib inhibited ALK and STAT-3 phosphorylation even in the presence of EGFR ligands, but failed to inhibit phosphorylation of EGFR and downstream Akt, and Erk1/2. Phosphorylation of ErbB4, a potential receptor for HB-EGF, was not affected by crizotinib or EGFR ligands. To further confirm the involvement of EGFR in crizotinib resistance induced by EGFR ligands, we knocked down EGFR by specific siRNAs in H2228 and H3122 cells (Fig. 3B). Although crizotinib markedly inhibited cell viability and all 3 EGFR ligands induced resistance in cells treated with scrambled siRNA, resistance to crizotinib was not induced by EGF, TGF- α , or HB-EGF in EGFR siRNA-treated cells, indicating that EGFR ligand-triggered crizotinib resistance is mediated by EGFR.

In parallel experiments, TAE684 inhibited ALK phosphorylation, thereby suppressing the phosphorylation of Akt, Erk1/2, and STAT-3 (Fig. 3C). HGF stimulated the phosphorylation of Met and its adaptor protein, Gab1, as described (29). TAE684 inhibited ALK and STAT-3 phosphorylation even in the presence of HGF, but failed to inhibit phosphorylation of Met and downstream Akt and Erk1/2. Phosphorylation of ErbB3, an adaptor of amplified, but not HGF-stimulated Met (30), was not affected by TAE684 or HGF. To further confirm the involvement of Met and Gab1 in HGF-induced TAE684 resistance, we knocked down Met, ErbB3, or Gab1 by specific siRNAs in H2228 and H3122 cells (Fig. 3D). TAE684 markedly inhibited the viability and HGF induced resistance in cells treated with scrambled siRNA. Importantly, treatment of cells with Met or Gab1, but not ErbB3, siRNA, induced TAE684 resistance, indicating the involvement of Met/Gab1 in HGF-induced resistance to TAE684.

Cross-talk of endothelial cells and fibroblasts reduces the sensitivity of EML4-ALK lung cancer cells to ALK inhibitors

To determine which types of host cells could produce EGFR ligands and HGF, we investigated production of these growth factors by various types of host stromal cells, comparing lung epithelial cells and cancer cells. The endothelial cell lines HMVEC produced discernible levels of EGFR ligands, including EGF, TGF- α , and HB-EGF, whereas fibroblasts produced a high level of HGF (Fig. 4A). EML4-ALK lung cancer cells (H2228, H3122, and




Figure 3. HGF and EGFR ligands trigger ALK inhibitor resistance via Met/Gab1 and EGFR, respectively. **A**, crizotinib inhibited the phosphorylation of ALK and STAT-3 but not that of EGFR, Akt, and Erk1/2 in the presence of EGF, TGF- α , or HB-EGF. Tumor cells were treated with or without crizotinib (100 nmol/L) for 1 hour and/or EGF (100 ng/mL), TGF- α (100 ng/mL), or HB-EGF (10 ng/mL) for 15 minutes. The cells were lysed and the indicated proteins were detected by immunoblotting. The results shown are representative of 3 independent experiments. **B**, control or EGFR-specific siRNAs were introduced into H2228 and H3122 cells. After 24 hours, the cells were incubated with or without crizotinib (100 nmol/L), and/or EGF (100 ng/mL), TGF- α (100 ng/mL), or HB-EGF (10 ng/mL) for 72 hours and lung cancer cell growth was determined by MTT assays. EGFR knockdown was confirmed by immunoblotting. The percentage of growth is shown relative to untreated controls. Each sample was assayed in triplicate, with each experiment repeated at least 3 times independently. **C**, TAE684 inhibited the phosphorylation of ALK and STAT-3, but not that of Met, Gab1, Akt, and Erk1/2 in the presence of HGF. Tumor cells were treated with or without TAE684 (100 nmol/L) for 1 hour and/or HGF (50 ng/mL) for 15 minutes. The cells were lysed and the indicated proteins were detected by immunoblotting. The results shown are representative of 3 independent experiments. **D**, control or Met, ErbB3, or Gab1-specific siRNAs were introduced into H2228 and H3122 cells. After 24 hours, the cells were incubated with or without TAE684 (100 nmol/L) and/or HGF (50 ng/mL) for 72 hours and lung cancer cell growth was determined by MTT assays. Met, Gab1, and ErbB3 knockdowns were confirmed by immunoblotting. The percentage of growth is shown relative to untreated controls. Each sample was assayed in triplicate, with each experiment repeated at least 3 times independently.

MANA2) and lung epithelial cells (BEAS-2B) produced low or no detectable levels of EGFR ligands or HGF. Interestingly, coculture of H2228 or H3122 cells with fibroblasts (MRC-5) significantly reduced their sensitivity to TAE684, an effect abrogated by anti-HGF antibody (Fig. 4B). Coculture with endothelial cells (HMVEC) also reduced sensitivity to crizotinib, an effect inhibited by anti-EGFR antibody (Fig. 4C).

These results suggested that host stromal cells, such as endothelial cells and fibroblasts, may regulate sensitivity to

ALK inhibitors by secreting EGFR ligands and HGF, respectively.

HGF derived from fibroblasts induces TAE684 resistance of EML4-ALK lung cancer cells *in vivo*

To investigate whether sensitivity to TAE684 could be affected by fibroblasts *in vivo*, we subcutaneously inoculated H2228 cells, with or without MRC-5 cells, into SCID mice. The tumors of mice injected with H2228 and MRC-5 cells grew slightly faster than those of mice injected with




Figure 4. Cross-talk of endothelial cells and fibroblasts reduces sensitivity of EML4-ALK lung cancer cells to ALK inhibitors. **A**, receptor ligand production was assayed in lung cancer (H2228, H3122, and MANA2), human bronchial epithelial cell (BEAS-2B), fibroblasts (MRC-5 and IMR-90), endothelial cells (HUVEC and HMVEC), and the macrophage differentiated cell line (PMA-U937). The cells were incubated in medium for 48 hours, culture supernatants were harvested, and EGF, TGF- α , HB-EGF, and HGF concentrations were determined by ELISA. All samples were assayed in triplicate. **B**, H2228 and H3122 cells were cocultured with or without fibroblasts, MRC-5 cells, and/or anti-HGF-neutralizing antibody (2 μ g/mL), in the presence or absence of TAE684 (100 nmol/L) for 72 hours, with cell growth determined by MTT assays. *, $P < 0.05$ (one-way ANOVA). Each experiment included triplicate determinations, and each experiment was repeated at least 3 times independently. **C**, endothelial cell-derived EGFR ligands induced crizotinib resistance in lung cancer cells with EML4-ALK fusion protein, an induction abrogated by blockade of EGFR. H2228 and H3122 cells were cocultured with or without endothelial cells, HMVECs, and/or anti-EGFR-neutralizing antibody (2 μ g/mL) in the presence or absence of crizotinib (100 nmol/L) for 72 hours, with cell growth determined as in **B**. *, $P < 0.05$ (one-way ANOVA). Each experiment included triplicate determinations, with each experiment repeated at least 3 times independently.

H2228 cells alone, but the difference was not statistically significant by day 8 (Fig. 5A). TAE684 treatment, beginning on day 4, caused marked regression of tumors in mice injected with H2228 cells alone, but not of tumors in mice injected with H2228 and MRC-5 cells, indicating that fibroblasts induced resistance to TAE684 *in vivo* (Fig. 5A). We confirmed that HGF was produced by MRC-5 cells *in vivo*. Although the tumors of mice injected with H2228 cells alone did not produce detectable levels of HGF, the tumors of mice injected with H2228 and MRC-5 cells produced high levels of HGF, started on day 4, but decreasing slightly on day 8 (Fig. 5B).

We further analyzed whether coinjection of MRC-5 cells restored the Akt pathway inhibited by TAE684 in the tumors. Western blotting showed that TAE684 treatment inhibited Akt phosphorylation, which was restored by coinjection of MRC-5 cells (Fig. 5C). These results suggested that fibroblasts produced HGF in the tumors

and restored Akt phosphorylation as a survival signal, as well as inducing resistance to TAE684 in EML4-ALK lung cancer cells *in vivo*.

Ligand-triggered resistance to ALK inhibitors is abrogated by inhibitors of both HGF-Met and EGFR

To establish novel strategies to treat EGFR ligand- or HGF-triggered resistance to ALK inhibitors, we examined the effect of combinations of ALK inhibitors with EGFR inhibitors (anti-EGFR Abs and reversible EGFR-TKIs) and HGF-Met inhibitors (anti-HGF Abs and Met-TKIs). Combined treatment with erlotinib, a reversible EGFR-TKI and cetuximab, an anti-EGFR Ab, successfully resensitized H2228 and H3122 cells to crizotinib even in the presence of the EGFR ligands, EGF (Fig. 6A), TGF- α (Fig. 6B), and HB-EGF (Fig. 6C). Moreover, the combination of HGF with E7050 (Met-TKI) or anti-HGF Ab resensitized cells to TAE684 (Fig. 6D).




Figure 5. HGF derived from fibroblasts induces TAE684 resistance of EML4-ALK lung cancer cells *in vivo*. **A**, fibroblast-derived HGF induced TAE684 resistance in H2228 tumors in SCID mice. H2228 cells (5×10^6), with or without MRC-5 cells (5×10^6), were inoculated subcutaneously into SCID mice on day 0. Starting on day 4, mice received oral TAE684 (1.25 mg/kg/d) or vehicle alone, with tumor size measured on days 4 and 8. Tumor volumes were calculated as described in Materials and Methods. Data shown are the representative of 2 independent experiments. Error bars indicate SEs of 6 mice. $P < 0.05$ was considered significant by one-way ANOVA. NS, not significant. **B**, HGF production by tumor tissues. Tumors were harvested on days 4 and 8 and lysed, and HGFs in the lysates were assayed by ELISA. All samples were assayed in triplicate. **C**, fibroblast-derived HGF induced TAE684 resistance via the Akt signal pathway *in vivo*. Tumors were harvested 2 hours after treatment on day 7 and lysed, and the lysates were analyzed by immunoblotting with the indicated antibodies, as described in Materials and Methods. The results shown are representative of 2 independent experiments.

Discussion

We have shown here that endothelial cells and fibroblasts, both components of the tumor microenvironment, secreted EGFR ligands and HGF, respectively, causing resistance to the ALK inhibitors crizotinib and/or TAE684 by activating bypass survival signals.

Of the EGFR ligands, EGF and TGF- α bind predominantly to EGFR, whereas HB-EGF binds to EGFR and ErbB4 (17). H2228 cells expressed both EGFR and ErbB4. Our results suggested that the bypass survival signal induced by EGFR ligands is mediated mainly by EGFR, as EGFR ligands markedly activated the phosphorylation of EGFR, not ErbB4. Moreover, knockdown of EGFR abrogated resistance caused by all EGFR ligands tested. EGFR ligand-triggered resistance was canceled by erlotinib or cetuximab, an anti-EGFR Ab, drugs approved for the treatment of patients with NSCLC and colorectal cancer. In addition, AP26113, an inhibitor of both ALK and EGFR, has been reported active against EML4-ALK lung cancer cells with amplified ALK and secondary mutations (7). Therefore, clinical trials are warranted to evaluate the efficacy and feasibility of combinations of an ALK inhibitor and these EGFR inhibitors to overcome ALK inhibitor resistance.

HGF, the sole ligand of Met (29), is important in EGFR-TKI resistance in EGFR-mutant lung cancer. HGF derived from cancer cells or stromal fibroblasts activated Met phosphorylation and stimulated the downstream Akt and Erk1/2 pathways (21, 22, 30) using Gab1, an adaptor protein for Met (31), triggering resistance to both reversible and irreversible EGFR-TKIs. In our Japanese cohort study of patients

with EGFR-mutant lung cancer, high HGF expression was detected in 61% of tumors with acquired resistance and in 29% of tumors with intrinsic resistance to EGFR-TKIs, suggesting the rationale of targeting HGF to overcome EGFR-TKI resistance (32). We also found that HGF triggered TAE684 resistance by activating Met and stimulating downstream Akt and Erk1/2 pathways using the adaptor protein Gab1. Because many anti-HGF Abs and Met-TKIs are being evaluated in clinical trials, HGF-triggered resistance to selective ALK inhibitors may be controlled by their combinations in the near future.

EGFR and Met have been shown to interact with each other and to mediate redundant signaling in lung cancer cells (33). In EGFR-mutant lung cancer cells, Met amplification causes EGFR-TKI resistance by triggering bypass survival signals using ErbB3, an adaptor protein (34). Met activation by HGF also triggers resistance to EGFR-TKIs that use Gab1 as an adaptor. In EML4-ALK lung cancer cells, both novel ALK second mutations and autocrine EGFR activation causes resistance to ALK inhibitors (11). We found that paracrine HGF and EGFR ligands could trigger ALK inhibitor resistance. Taken together, these findings suggest that signaling by EGFR and Met is crucial for the survival of lung cancer cells with EGFR mutations and EML4-ALK translocations under inhibition of these driver oncogenes.

We found that resistance to TAE684 was induced by both EGFR ligands and HGF, whereas crizotinib resistance was induced by EGFR ligands alone, a finding that may be due to the dual activities of crizotinib on ALK and